Skip to main content
NCBI home page
Molecular Therapy Oncolytics logoLink to Molecular Therapy Oncolytics
. 2015 Jun 10;2:15007. doi: 10.1038/mto.2015.7

L-Asparaginase delivered by Salmonella typhimurium suppresses solid tumors

Kwangsoo Kim 1,2, Jae Ho Jeong 1,2, Daejin Lim 1,2, Yeongjin Hong 1,2, Hyung-Ju Lim 1,2, Geun-Joong Kim 3, So-ra Shin 3, Je-Jung Lee 2,4, Misun Yun 2,5, Robert A Harris 6, Jung-Joon Min 2,5,*, Hyon E Choy 1,2,*
PMCID: PMC4845971  PMID: 27119104

Abstract

Bacteria can be engineered to deliver anticancer proteins to tumors via a controlled expression system that maximizes the concentration of the therapeutic agent in the tumor. L-asparaginase (L-ASNase), which primarily converts asparagine to aspartate, is an anticancer protein used to treat acute lymphoblastic leukemia. In this study, Salmonellae were engineered to express L-ASNase selectively within tumor tissues using the inducible araBAD promoter system of Escherichia coli. Antitumor efficacy of the engineered bacteria was demonstrated in vivo in solid malignancies. This result demonstrates the merit of bacteria as cancer drug delivery vehicles to administer cancer-starving proteins such as L-ASNase to be effective selectively within the microenvironment of cancer tissue.

Introduction

Bacterial cancer therapy relies on bacteria that can target solid tumors and proliferate therein (reviewed in refs. 1–3). Although the mechanism underlying this phenomenon has yet to be understood, an immune-privileged environment in tumor tissue should offer a sanctuary for intratumoral bacteria, which can proliferate up to 109 colony forming unit/g tissue.1,4 Such bacterial proliferation, especially that of Salmonella spp. or Clostridium spp., results in tumor regression.5–7 Bacteria equipped with anticancer cargo proteins are often more effective tumor suppressors than bacterial monotherapy.8–10 Such anticancer proteins include cytotoxic agents, cytokines that stimulate immune cells to kill cancer cells, and tumor antigens that sensitize the immune system against cancer cells.1,11 Since most, if not all, of the anticancer proteins are more or less toxic to normal cells, they should be expressed exclusively in intratumoral bacteria.12–15

Asparaginase (L-ASNase) of Escherichia coli origin is a universal component of therapy for acute lymphoblastic leukemia.16 L-ASNase catalyzes the deamination of asparagine to aspartate and to a lesser extent the deamination of glutamine to glutamate.17 Both activities may be needed for therapeutic effectiveness against malignancies.17,18 Asparagine depletion leads to an adaptive response in which uncharged tRNA activates the serine/threonine kinase GCN2 (ref. 19). GCN2 phosphorylates the translation initiation factor eIF2á, which acts as a dominant inhibitor of the guanine nucleotide exchange factor eIF2B, which prevents eIF2 recycling during protein synthesis, resulting in inhibition of global protein synthesis.20 Unless asparagine can be resynthesized rapidly enough to keep its tRNA charged, cells undergo apoptotic cell death for a downregulation of the overall rate of protein synthesis.21

The glutaminase activity of L-ASNase also promotes apoptosis. A high intracellular glutamine concentration promotes the uptake of leucine which stimulates protein synthesis by activating mTORC1.22 The reduction of mTORC1 activity when glutamine is low suppresses protein synthesis and augments the effects of asparagine deficiency on apoptosis. Furthermore, mitochondrial catabolism of glutamine can rescue tumor cells from asparagine deficiency by providing the four carbons and two nitrogens required for asparagine synthesis.23 What’s more, glutamine is required for the resynthesis of asparagine from aspartate by asparagine synthetase (ASNS).24 ASNS expression is normally low in cells but activation of the GCN2-eIF2á system promotes translation of the transcription factor ATF4 (ref. 25) which induces ASNS expression. Provided sufficient glutamine is present, ASNS can promote asparagine accumulation which suppresses GCN2 and rescues the cells from apoptosis. L-ASNase has been used successfully to treat blood borne acute lymphoblastic leukemia tumors via intravenous (i.v.) administration26 because rescue circuits fail in acute lymphoblastic leukemia cells.27,28 Prior to this study, it was rarely possible to treat solid tumors with L-ASNase,29 in part because systemic treatment with the high concentrations of L-ASNase needed to affect the asparagine concentration in the tumor is frequently accompanied by serious side-effects including anaphylactic shock, coagulopathies as well as liver and pancreatic toxicity.30 Furthermore, it has been thought that upregulation of ASNS would rescue the tumor from apoptosis.31 However, in this study, Salmonellae was engineered to express large amounts of L-ASNase (EC2) of E. coli origin selectively within solid tumors using a remote gene control system derived from araPBAD inducible by systemic administration lf soluble activator, L-arabinose.8 This is the first demonstration of antitumor efficacy of targeted L-ASNasein solid tumor models.

Results

Cytotoxicity associated with L-ASNase expressed from Salmonellae in vitro

In an attempt to treat solid malignancies with L-ASNase, we constructed a plasmid, pASN, carrying the asnB gene of E. coli B (BL21) under the control of the araBAD promoter(PBAD) of the E. coli arabinose operon, which is inducible by L-arabinose, by cloning the 1,047 bp PCR-amplified asnB open reading frame into GlmS+p (Supplementary Figure S1a).32 The GlmS+p is a balanced lethal host vector system32 that relies on the phenotype of the GlmS- mutant. This mutant undergoes lysis when grown in the absence of N-acetyl-D-glucosamine (GlcNac) unless complemented by a plasmid carrying the glmS gene.32 We used a highly attenuated S. typhimurium strain (14028s) defective in ppGpp synthesis33and carrying a mutation in the glmS gene (ΔppGpp S. typhimurium), and transformed it with pASN. The Salmonellae were grown in Luria Broth supplemented with L-arabinose (0.2%; ref. 34). The bacterial culture was harvested, the supernatant medium was separated from the cells by centrifugation and filtration, and each fraction was analyzed for L-ASNase by western blotting using a specific antibody (Supplementary Figure S1b). L-ASNase was induced by the L-arabinose supplementation. Moreover, a significant fraction of L-ASNase was secreted, and thus found in the supernatant, as in E. coli.35 Subsequently, proteins in the culture supernatant were tested for L-ASNase activity by measuring cytotoxicity in three cultured cancer cell lines: mouse MC38 colon cancer cells, mouse 4T-1 breast cancer cells, and human AsPC-1 pancreatic cancer cells (Figure 1). The Jurkat T-cell leukemia line and the immortalized noncancerous HEK293 kidney cell line, sensitive and insensitive, respectively, to L-ASNase, were included as positive and negative controls, respectively. The cells were exposed for 24, 48, and 72 hours to the concentrated culture supernatants (0.2 mg/ml) of Salmonella carrying parental plasmid (glmS+p) or pASN, and cell death was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay. All cell lines except HEK293 showed varying degrees of sensitivity (60–80%) to L-ASNase-containing bacterial culture supernatant and to L-ASNase used clinically (Leunase, 5 units/ml, Kyowa Hakko Kirin, Japan). By contrast, only marginal cytotoxicity was observed upon exposure to the culture supernatant of Salmonella carrying glmS+p, confirming the L-ASNase specificity of the cytotoxicity observed upon exposure to the supernatants of Salmonella carrying pASN. It was also noted that the suppression of cell growth by the L-ASNase-containing bacterial supernatant was immediate irrespective of growth rate of the tumors, among those tested (Supplementary Figure S2).

Figure 1.

Figure 1

Open in a new tab

Cell death induced by the L-ASNase present in the bacterial culture medium. Salmonellae carrying pASN (SL/pASN) or parental vector GlmS+p32 were grown in the presence of L-arabinose. The spent medium was collected after centrifugation and filtration, and concentrated to 50 mg protein/ml. Cytotoxicity (200 mg) was tested using cultured animal cells. The assay included 5 units of Leunase as control. Cell death was measured after 24, 48, and 72 hours by MTT assay.41 Actual viable cells (A540 values) ± SD were plotted as function of time. Asterisks (*) indicate significant differences compared to phosphate-buffered saline (*P = 0.0097, ** P = 0.0119).

Jurkat T cells treated with L-ASNase have been reported to undergo apoptosis.36 In order to assess the cell death mechanism of those tested cancer cell lines, we measured Annexin V, which is associated with apoptotic cell death. Total protein content was extracted from the cells exposed for 36 hours to the L-ASNase-containing bacterial supernatant, and analyzed for Annexin V expression by western blotting. We observed a marked increase in the level of Annexin V in all cancer cells tested (Supplementary Figure S3a). This result was verified by immunofluorescence staining (Supplementary Figure S3b). L-ASNase-containing bacterial supernatant caused a considerable accumulation of Annexin V on the cell surface compared to phosphate-buffered saline (PBS). We concluded that the L-ASNase expressed and secreted by Salmonellae induces apoptotic cell death in cancer cells in vitro.

Antitumor efficacy of Salmonella-derived L-ASNase in mouse models

First, we measured the expression of L-ASNase under the control of PBAD in Salmonella targeted to MC38 tumors ectopically grafted in mice. 1 × 107 ΔppGpp S. typhimurium transformed with pASN was i.v. injected into the tumor-bearing mice and the L-ASNase was induced by intraperitoneal (i.p.) injection of L-arabinose 4 days postinoculum (dpi). We have not noted any sign of serious local or systemic inflammatory reaction following the induction of cytotoxic antitumor protein in intratumoral Salmonella at 3 dpi.9 Eight hours after the administration of L-arabinose, tumors (n = 2) were harvested, extracted, and the extracts separated by centrifugation into a supernatant containing subcellular molecules and a pellet containing macromolecules including intact bacteria that were analyzed for the expression and secretion of L-ASNase by western blotting (Figure 2a L-ASNase-specific bands(32 kDa) were detected in the animals administered with L-arabinose. Moreover, a considerable amount of L-ASNase was detected in the supernatant, approximately a quarter of the amount found in the pellet. This was further verified by immunohistochemical staining of the tumor tissue samples with L-ASNase-specific antibody (Figure 2b). Significantly elevated levels of L-ASNase were detected in mice treated with Salmonellae carrying pASN only after L-arabinose administration. It should be noted that L-ASNase-specific antibody also stained endogenous Salmonellae L-ASNase which shares 93% amino acid identity with E. coli L-ASNase (Salmonella alone), although the signal was weaker.

Figure 2.

Figure 2

Open in a new tab

Expression and release of L-ASNase from intratumoral Salmonellae carrying pASN. Mice bearing MC38 tumors were injected with Salmonellae carrying pASN(SL/pASN). L-ASNase was induced by i.p. injection of L-arabinose (60 mg), and the tumor tissues were excised 8 hours after the induction, homogenized, and centrifuged (5,000 × g, 5 minutes) to obtain the “supernatant” devoid of intact bacteria and the “pellet” containing macromolecules. 100 µg of pellet protein and supernatant protein were run on a 10% SDS PAGE gel and probed with L-ASNase-specific antibody (a). The same tissue samples were analyzed by confocal microcopy after immunofluorescence staining of L-ASNase (b). Salmonellae were stained in red and L-ASNase in green using specific antibodies.

Subsequently, we assessed the antitumor efficacy of the Salmonellae transformed with pASN in mice bearing tumors: (i) MC38 tumors in C57BL/6 mice, (ii) 4T-1 tumors in BALB/c mice, and (iii) AsPC-1 tumors in BALB/c athymic nu−/nu−mice (Figure 3). Salmonellae carrying either pASN or GlmS+p were injected through the tail vain when the tumor reached ~120 mm3 (ref. 32). L-ASNase was induced by intraperitoneal injection of L-arabinose (60 mg/day/mouse) from 3 dpi, and changes in tumor size were recorded. The results showed the greatest antitumor efficacy with Salmonellae carrying L-ASNase induced by L-arabinose administration. We observed an antitumor effect with Salmonella monotherapy, which was comparable to 4T-1 or smaller than that observed with Salmonella carrying pASN without L-arabinose administration (MC38), but measurably greater than PBS. At the end of the experiment, the mean size of MC38 tumors (at 33 days), 4T-1 tumors (at 35 days), and AsPC-1 tumors (at 45 days) treated with Salmonellae expressing L-ASNase was 463.7, 367.4, and 331 mm3, respectively, while tumors treated with bacteria carrying pASN without induction, that of bacteria carrying parental plasmid, and that of PBS all reached >1,000 mm3. Consequently, survival was substantially prolonged in the animals that received bacteria expressing L-ASNase compared to those in other groups (P < 0.001) (middle panels). Taken together, we concluded that the L-ASNase expressed and released from Salmonellae was effective at suppressing tumor growth in the mouse models used.

Figure 3.

Figure 3

Open in a new tab

Antitumor effects of Salmonellae carrying L-ASNase in vivo. The antitumor effect of Salmonellae carrying pASN (1 × 107 colony forming unit) was measured using (a) MC38 tumors in C57BL/6 mice, (b) 4T-1 tumors in BALB/c mice, and (c) AsPC-1 tumors in BALB/c athymic nu-/nu- mice. The tumor-bearing mice were treated with phosphate-buffered saline (n = 6), Salmonellae carrying empty vector, GlmS+p32 (n = 6), or Salmonellae carrying pASN(SL/pASN) (n = 6 each group. L-arabinose (60 mg) was administered i.p. every day starting 4 days after the treatment with engineered S. typhimurium (SL/pASN (Ara+)). Representative gross morphological changes are shown on the right. Changes in tumor size after the bacterial treatment are shown on the left. Error bars correspond to upper or lower 95% CIs. Kaplan-Meier survival curves of mice bearing MC38 (*P < 0.001, **P = 0.001, ***P = 0.005), 4T-1 (*P < 0.001, **P = 0.0019) or AsPC-1 tumors (*P < 0.001, **P = 0.001, ***P = 0.003) are shown in the middle. Data represent mean ± SD, and asterisks (*) indicate significant differences compared to phosphate-buffered saline controls (*P < 0.05).

Correlation between antitumor efficacy and L-ASNase activity

Since L-ASNase was delivered by Salmonellae in this study, it was not possible to determine dose-dependent effect using the conventional method. To this end, we employed mutant L-ASNases defective in enzyme activity. We chose two amino acid substitution mutants carrying Gly in place of Asn24 or Asp124, N24G and D124G substitution mutants, respectively, reported to have 45 and 3% activity compared to the wild-type protein, respectively.37 pASN carrying the above mutations in the asnB gene was constructed and named pASNN24G and pASND124G. ΔppGpp Salmonellae transformed with these plasmids were grown in LB in the presence or absence of L-arabinose as described previously (Supplementary Figure S1). The bacterial culture was divided into bacterial pellet and medium, and assessed for the presence of ASNase by western blot (Figure 4a). The mutant L-ASNases, as well as the wild-type enzyme, were induced with L-arabinose and secreted into the medium. Subsequently, the bacterial supernatants containing the mutant L-ASNases were assayed for enzyme activity (Figure 4b). Mutant L-ASNases with N24G or D124G substitution showed ~50% and <10% activity, respectively, compared to the wild-type control, as reported previously.37 Cytotoxicity was assessed in vitro by MTT assay using cultured cancer cells: MC38, 4T-1, and AsPC-1 (Figure 4c). Analysis of the relationship between L-ASNase activities and cancer cell viabilities yielded strong Pearson’s correlations of r = −0.97567 (P < 0.0001) with MC38, r = −0.98707 (P < 0.0001) with 4T-1, and r = −0.97700 (P < 0.0001) with AsPC-1 (Supplementary Figure S4). To test the antitumor effect of mutant L-ASNases in vivo, MC38-bearing BL/6 mice were prepared as described previously (Figure 2) and injected through i.v. route with ΔppGpp Salmonellae transformed with either pASNN24G or pASND124G. For induction, mice were injected i.p. with L-arabinose at 3 dpi. The gross morphology of tumors extracted at 3 dpi are shown in Figure 5a, and quantification of tumor size in Figure 5b. Animal survival is shown in Figure 5c. A direct correlation between L-ASNase activity and regression of tumor size/extension of survival was noted in vivo.

Figure 4.

Figure 4

Open in a new tab

Expression and cytotoxic activity of mutant L-ASNases. (a) Expression of two amino acid substitution mutants (see text) and wild-type L-ASNases in the media supernatant and bacterial pellet upon induction with L-arabinose. See legend of Supplementary Figure S1 for details. (b) The spent media containing the mutant L-ASNases were assayed for enzyme activity. (c) Cytotoxicity associated with these mutant L-ASNases was measured in vitro using cultured MC38 (left), 4T-1 (middle), and AsPC-1 (right) by MTT assay. See legend of Figure1 for details. Data represent mean ± SD.

Figure 5.

Figure 5

Open in a new tab

Antitumor effect of the mutant L-ASNases expressed by intratumoral Salmonellae. Salmonellae (1 × 107 colony forming unit) carrying pASN, pASNN24G, or pASND124G, were injected intravenously into C57BL/6 mice carrying MC38 tumors (n = 5 each group). (a) The change in gross morphology of the tumor tissue after bacterial treatment. (b) The changes in tumor size after bacterial treatment and (c) Kaplan–Meier survival curves of the tumor-bearing mice. Data represent mean ± SD, and asterisks (*) indicate significant differences compared to phosphate-buffered saline (*P < 0.05).

Correlation between antitumor effect and local concentration of L-ASNase

To understand the distribution of L-ASNase expressed and secreted by tumor-targeted Salmonellae, we analyzed serum and tumor tissue in MC38-bearing mice by western blot using L-ASNase-specific antibody (Figure 6a) and by enzymatic activity assay (Figure 6b). Leunase (400 KU) injected intravenously was used as a control. Tissue samples were collected over time after administration of L-arabinose into mice treated with Salmonellae or after Leunase administration. In the animals treated with Leunase, a considerable amount of L-ASNase was detected in the serum at the early time point (4 hours) and diminished over time, but none was detected in the tumor tissue. By contrast, in mice treated with Salmonellae expressing L-ASNase, the protein was detected only in tumor tissue and increased dramatically as time progressed up to 48 hours. Accordingly, annexin V was induced in the tumor tissue only when the mice received Salmonellae expressing L-ASNase. Intravenous administration of Leunase to MC38-bearing mice did not reduce tumor size (Supplementary Figure S5a and a high dose (400KU) shortened animal survival (Supplementary Figure S5b, which should be ascribed to the side effects.30 By contrast, a direct intratumoral injection of Leunase resulted in a notable reduction of tumor size (Figure 7a) (for Leunase 40KU versus control group, difference = 336 mm3, 95% CI = 220–451, P = 0.008; for Leunase 4KU versus control group, difference = 607 mm3, 95% CI = 532–681, P = 0.008), as it was detectable at the tumor tissues by western blotting (Figure 7). Taken together, we concluded that L-ASNase can be used to treat solid malignancies if delivered by a carrier such as Salmonellae to intratumoral sites so that a copious concentration is maintained in situ.

Figure 6.

Figure 6

Open in a new tab

Distribution of L-ASNase in blood and tumor tissue. The C57BL/6 mice bearing MC38 tumors were treated with either 400 KU Leunase or Salmonellae carrying pASN (SKS1002/pASN) and analyzed for distribution of L-ASNase. In the latter case, L-ASNase was induced by a single administration of L-arabinose 4 days after bacterial injection (t = 0). Whole serum and tumor tissues (100 µg) were collected after the treatment and subjected to quantification of L-ASNase by western blotting (a). The same tumor tissues were analyzed for Annexin V and β-actin, the latter as a loading control. (b) L-ASNase activity measured using enzyme assay kit in the serum and tumor tissue in the mice treated as described above (n = 4 for each group). Data represent mean ± SD.

Figure 7.

Figure 7

Open in a new tab

Antitumor effect of Leunase after intratumoral injection. Leunase was directly injected into MC38 tumors in C57BL/6 mice (n = 5) at 4 KU and 40 KU daily for 3 days. On day 4, animals were sacrificed and tumor size was estimated as described in the legend of Figure 5 (a). (b) Gross morphology of the tumor tissues. (c) Distribution of L-ASNase in blood and tumor tissue after the Leunase treatment by western blotting. Data represent mean ± SD, and asterisks (*) indicate significant differences compared to phosphate-buffered saline (*P < 0.05).

Discussion

Many tumors exhibit deficiencies in the synthesis of one or more amino acids, forcing a reliance on extracellular pools of these amino acids for protein biosynthesis. Therefore, depletion of such amino acid(s) would provide cancer cell-selective therapy with few side effects. L-ASNase is used to mediate the degradation of such amino acids for therapeutic purposes; however, undesirable toxicity hampers systemic injection.30 We have also seen a deleterious effect of high-dose L-ASNase injected intravenously (Supplementary Figure S5b). This could be caused by the fact that L-ASNase prevents several forms of glycosylation, including sialylation, in newly synthesized proteins.38,39 In addition, E. coli L-ASNase possesses glutaminase activity, which results in deprivation of L-glutamine.39 Whereas, bacterial tumor therapy circumvents the systemic injection of high-dose L-ASNase, thereby avoiding systemic toxicity while maintaining sufficient levels inside the tumor tissue.

Successful bacterial antitumor therapy, in which intratumoral bacteria are used to express anticancer proteins, requires certain provisions, as follows. First, the antitumor protein should be expressed selectively at the tumor site, as demonstrated in this study. Since bacteria administered intravenously initially localize to reticuloendothelial organs,8,9 the protein drugs should be expressed only when the bacteria have cleared reticuloendothelial organs and accumulated exclusively in the targeted tumor tissue; this normally occurs 3 days after administration. We have shown that controlled expression of cytotoxic proteins at 3 dpi does not cause any notable systemic toxicity.9 Second, the antitumor protein must be released. Fortunately, a significant fraction of the L-ASNase of E. coli origin was secreted from Salmonellae.  E. coli L-ASNase (EC2) is a periplasmic enzyme that contains a typical secretary signal peptide of 22 residues at its amino terminus. When the enzyme is secreted to the periplasm, the signal peptide is removed to yield a mature protein with an N-terminal leucine residue.35 Proteins secreted into the periplasm tend to leak out through the bacterial outer membrane. Lastly, but most importantly, antitumor proteins should act on the cancer cell surface or the tumor microenvironment, rather than on intracellular targets. In the latter case, the barely permeable cell membrane remains a formidable barrier to efficacy. A widely used strategy uses cell-penetrating peptides (CPPs) to improve intracellular uptake. Successful intracellular delivery of antitumor proteins using this strategy requires optimization of CPP for individual anticancer proteins.12 Given these considerations, L-ASNase is an anticancer cargo protein that is appropriate for delivery to the tumor microenvironment by tumor-targeting bacteria.

We demonstrated a linear relationship between in vitro cytotoxicity and in vivo tumor regression using mutant L-ASNases with varying levels of activity (Figures 4 and 5). The linear relationship revealed the dose-dependent effect of L-ASNase in vivo and was comparable with that determined using cultured cells in vitro. If bacterial therapy with ASNase-expressing Salmonellae was to be employed post-surgical elimination of the tumor, prognosis could be assessed based on the in vitro sensitivity of the cancer tissue to L-ASNase. In practice, bacterial therapy with Salmonella expressing L-ASNase, would be useful to treat cancer patients with multiple organ metastases since bacteria would be capable of targeting tumor of any kind with size as small as 100 mm.34

Materials and Methods

Plasmid construction

DNA encoding ASNase II (asnB) was amplified from the genomic DNA of E. coli B strain (BL21)40 using two sets of primers: L-ASN1 (5′-GG GAA TTC ATGGAGTTT TTC AAA AAG-3′) and L-ASN2 (5′-GGG TCT AGA TTA GTA CTG ATT GAA GAT CTG CTG-3′). The 1,047 kb DNA fragment of asnB was inserted into GlmS+p32 using Eco RI and Xba I restriction enzyme sites to generate pASN. The mutant L-ASNases were generated by site-directed mutagenesis (Stratagene, San Diego, CA) using pASN and the following primers: P1, 5′-GACTCCGCAACCAAATCTGGCTACACAGTGGGTAAAG-3′ for N24G; and P2, 5′-ACGTCTATGAGCGCAGGCGGTCCATTCAACCTGT-3′ for D124G. All constructs were verified by automated DNA sequencing.

Bacterial growth conditions

Bacteria were grown in LB medium (Difco Laboratories) containing 1% NaCl. For solid support medium, 1.5%-bacto agar was included. All media were supplemented with antibiotics as follows: ampicillin at 100 µg/ml, kanamycin at 50 µg/ml, and chloramphenicol at 10 µg/ml.

Cell culture

MC38 and 4T-1 cell lines were grown in high-glucose Dulbecco’s modified Eagle medium, HEK293 in EME medium, and AsPC1 and Jurkat T in RPMI1640 medium, containing 10% FBS and 1% penicillin-streptomycin.

Protein (L-ASNase) preparation

The spent bacterial media and bacterial pellets were prepared as follows after centrifugation (5,000 ×g, 5 minutes) and filtration (0.45 µm): the pellets were lysed by sonication in lysis buffer (10 mmol/l lysozyme, 10% sodium dodecyl sulfate (SDS)), and the supernatants were filtered (0.22 µm pore filter) and concentrated using Centricon devices (AmiconR Ultra, 10K pore filter, Millipore). The proteins were precipitated with 10% trichloroacetic acid (1 hour, 4 °C) and dissolved in PBS. Leunase was purchased from Kyowa Hakko Kirin, Japan.

Western analysis

Mammalian cell lines and tumor tissues were lysed by sonication in RIPA buffer (50 mmol/l Tris-HCl pH 7.5, 150 mmol/l NaCl, 1% NP40, 0.5% sodium deoxycholate, and 0.1% SDS) containing protease inhibitors (protease inhibitor mixture; Roche Applied Science). Tumor tissue were extracted, homogenized with a motor-driven tissue homogenizer (Ika-Werke, Staufen, Germany), and separated to supernatant and pellet by centrifugation (5,000 × g, 5 minutes). The pellets were lysed by sonication as described above. The supernatants were treated with 10% trichloroacetic acid (1 hour, 4 °C) for precipitation of proteins. For western blot analysis, protein samples were boiled for 5 minutes, separated by 10% SDS-PAGE, and transferred to nitrocellulose membrane (Amersham Biosciences). The membrane was blocked with 5% skim milk and probed with a rabbit anti-L-ASNase antibody (1:1,000; Abcam), rabbit anti-Annexin V antibody (1:2,000, Abcam), or mouse anti-β-Actin antibody (1:5,000, Santa Cruz) at 4 °C overnight. The membrane was then incubated with anti-mouse or anti-rabbit IgG linked to horseradish peroxidase (Sigma-Aldrich, UK) for 1 hour and bound proteins were visualized by ECL (Amersham Biosciences).

Cell viability assay (MTT)

The MTT assay was performed to evaluate cell proliferation. The cells (3 × 103 per well) were seeded into 96-well culture plates in 100 µl medium at 37 °C with 5% CO2. After overnight incubation, the supernatant was removed and fresh medium was added. The cells were incubated with concentrated bacterial supernatant (0.2 mg/ml) and the number of live cells was determined using MTT assay kit (Sigma-Aldrich, St. Louis, MO).

Immunofluorescence and confocal microscopy

The cells were grown on sterilized glass cover slips, fixed with 4% paraformaldehyde, and blocked with 0.1% BSA (bovine serum albumin) in PBS. Subsequently, the samples were stained with rabbit anti-Annexin Va ntibody (1:200, Abcam) in PBS and Alexa 488-conjugated secondary antibody (1:500, Invitrogen). The samples were also stained with Texas Red-X phalloidin (1:500, Invitrogen) and DAPI/antifade (1:200, Invitrogen). Images were captured with a Bio-Rad confocal microscope (Bio-Rad laboratories, Hercules, CA).

Tissue immunofluorescence staining

Tumor tissues were fixed with 4% paraformaldehyde in PBS overnight at room temperature, and embedded and frozen using optical optimal cutting temperature compound (Tissue-Tek). The tumors were sliced into 6-µm thick sections using a microtome-cryostat. The tissue sections were collected on aminopropyltriethoxysilane-coated slides. The slides were washed using PBS (pH7.4) for complete removal of the optimal cutting temperature compound and incubated with primary antibodies, rabbit anti-L-ASNase antibody (1:100, Abcam), and mouse anti-Salmonella antibody (1:100, Abcam), overnight at 4 °C. Alexa 488-conjugated goat anti-rabbit antibody (1:100) and Alexa 568-conjugated goat anti-mouse antibody (1:100) were used as secondary antibodies. The samples were mounted with DAPI/antifade (1:200, Invitrogen).

Animal experiments

Five- to 6-week-old male mice (20–30 g body weight) were purchased from Samtako Company, Korea. All animal care, experiments, and euthanasia were performed in accordance with the protocols approved by the Chonnam National University Animal Research Committee. Animals were anesthetized with isoflurane (2%) for imaging or a mixture of ketamine (200 mg kg−1) and xylasine (10 mg kg−1) for surgery. Mice carrying subcutaneous tumors were generated as follows: tumor cells cultured in vitro were harvested, suspended in 100 µl PBS, and injected subcutaneously into the right thigh (1 × 106 cells for 4T-1 and MC38, and 1 × 107 cells for AsPC1). Tumor volumes (mm3) were estimated using the formula (L × H × W)/2 where L is the length, W is the width, and H is the height of the tumor in millimeters. 1 × 107 ΔppGpp S. typhimurium transformed with pASN suspended in PBS was injected through the tail vain when the tumor reached ~120 mm3. L-ASNase was induced by intraperitoneal (i.p.) injection of L-arabinose 4 days postinoculum (dpi) (60 mg/day/mouse).

Injection of bacteria into animals

S. typhimurium suspended in 100 µl PBS were injected intravenously into tumor-bearing mice through the lateral tail vein using an l cc insulin syringe.

Determination of L-ASNase activity

Bacterial supernatants of native and mutants L-ASNase were prepared as concentrated forms for the enzymatic assay. Serum samples were directly used for the enzyme assay. Tumor tissue samples were extracted by the  4 volumes of assay buffer in Asparaginase Activity Assay kit (Abcam, ab107922), and insoluble materials were removed by the centrifugation. Levels of L-ASNase enzymatic activity in the bacterial supernatants (100 µg), serum (10 µl), and tumor tissues (100 µg) were assessed with the Asparatinase Activity assay kit, for a quantitative enzyme assay.

Correlative analysis

Pearson’s correlation coefficients in Supplementary Figure S5 were computed for the relationship between L-ASNase activities and cell viabilities using GraphPad Prism 5.01, including P values for the one-tailed test of significance

Statistical analysis

Statistical analysis was performed using the SPSS 18.0 statistical package (SPSS, Chicago, IL). A two-tailed Student’s t-test was used to assess the statistical significance of tumor growth differences between treatment groups. P < 0.05 was considered statistically significant.

Acknowledgments

We thank Taewon Lee at Korea University for statistical analyses. J.J.M. was supported by Leading Foreign Research Institute Recruitment Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (MEST) (2011-0030034), and H.E.C. was by the NRF (No. 2014R1A2A1A10051664). K.S.K was supported by Basic Science Research Program (NRF) (No. 2014R1A1A2004637) and J.H.J was by Basic Science Research Program (NRF) (No. 2014R1A1A2006327) of Korea. R.A.H was supported by United States Veteran Affairs Merit Review Award.

Supplementary Figure S1
Click here for additional data file. (108.3KB, pdf)
Supplementary Figure S2
Click here for additional data file. (80.1KB, pdf)
Supplementary Figure S3
Click here for additional data file. (134.1KB, pdf)
Supplementary Figure S4
Click here for additional data file. (97.2KB, pdf)
Supplementary Figure S5
Click here for additional data file. (59.1KB, pdf)

References

  1. Forbes, NS (2010). Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer 10: 785–794. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Hoffman, RM and Zhao, M (2014). Methods for the development of tumor-targeting bacteria. Expert Opin Drug Discov 9: 741–750. [DOI] [PubMed] [Google Scholar]
  3. Chorobik, P, Czaplicki, D, Ossysek, K and Bereta, J (2013). Salmonella and cancer: from pathogens to therapeutics. Acta Biochim Pol 60: 285–297. [PubMed] [Google Scholar]
  4. Min, JJ, Kim, HJ, Park, JH, Moon, S, Jeong, JH, Hong, YJ et al. (2008). Noninvasive real-time imaging of tumors and metastases using tumor-targeting light-emitting Escherichia coli. Mol Imaging Biol 10: 54–61. [DOI] [PubMed] [Google Scholar]
  5. Pawelek, JM, Low, KB and Bermudes, D (1997). Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res 57: 4537–4544. [PubMed] [Google Scholar]
  6. Zhao, M, Yang, M, Li, XM, Jiang, P, Baranov, E, Li, S et al. (2005). Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci USA 102: 755–760. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Agrawal, N, Bettegowda, C, Cheong, I, Geschwind, JF, Drake, CG, Hipkiss, EL et al. (2004). Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci USA 101: 15172–15177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Nguyen, VH, Kim, HS, Ha, JM, Hong, Y, Choy, HE and Min, JJ (2010). Genetically engineered Salmonella typhimurium as an imageable therapeutic probe for cancer. Cancer Res 70: 18–23. [DOI] [PubMed] [Google Scholar]
  9. Jiang, SN, Park, SH, Lee, HJ, Zheng, JH, Kim, HS, Bom, HS et al. (2013). Engineering of bacteria for the visualization of targeted delivery of a cytolytic anticancer agent. Mol Ther 21: 1985–1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Wall, DM, Srikanth, CV and McCormick, BA (2010). Targeting tumors with salmonella Typhimurium- potential for therapy. Oncotarget 1: 721–728. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Bermudes, D, Low, B and Pawelek, J (2000). Tumor-targeted Salmonella. Highly selective delivery vectors. Adv Exp Med Biol 465: 57–63. [DOI] [PubMed] [Google Scholar]
  12. Jeong, JH, Kim, K, Lim, D, Jeong, K, Hong, Y, Nguyen, VH et al. (2014). Anti-tumoral effect of the mitochondrial target domain of Noxa delivered by an engineered Salmonella typhimurium. PLoS ONE 9: e80050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ganai, S, Arenas, RB and Forbes, NS (2009). Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice. Br J Cancer 101: 1683–1691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Ryan, RM, Green, J, Williams, PJ, Tazzyman, S, Hunt, S, Harmey, JH et al. (2009). Bacterial delivery of a novel cytolysin to hypoxic areas of solid tumors. Gene Ther 16: 329–339. [DOI] [PubMed] [Google Scholar]
  15. Flentie, K, Kocher, B, Gammon, ST, Novack, DV, McKinney, JS and Piwnica-Worms, D (2012). A bioluminescent transposon reporter-trap identifies tumor-specific microenvironment-induced promoters in Salmonella for conditional bacterial-based tumor therapy. Cancer Discov 2: 624–637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Wriston, JC Jr and Yellin, TO (1973). L-asparaginase: a review. Adv Enzymol Relat Areas Mol Biol 39: 185–248. [DOI] [PubMed] [Google Scholar]
  17. Willems, L, Jacque, N, Jacquel, A, Neveux, N, Maciel, TT, Lambert, M et al. (2013). Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood 122: 3521–3532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ehsanipour, EA, Sheng, X, Behan, JW, Wang, X, Butturini, A, Avramis, VI et al. (2013). Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine. Cancer Res 73: 2998–3006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hao, S, Sharp, JW, Ross-Inta, CM, McDaniel, BJ, Anthony, TG, Wek, RC et al. (2005). Uncharged tRNA and sensing of amino acid deficiency in mammalian piriform cortex. Science 307: 1776–1778. [DOI] [PubMed] [Google Scholar]
  20. Clemens, MJ (2001). Initiation factor eIF2 alpha phosphorylation in stress responses and apoptosis. Prog Mol Subcell Biol 27: 57–89. [DOI] [PubMed] [Google Scholar]
  21. Ueno, T, Ohtawa, K, Mitsui, K, Kodera, Y, Hiroto, M, Matsushima, A et al. (1997). Cell cycle arrest and apoptosis of leukemia cells induced by L-asparaginase. Leukemia 11: 1858–1861. [DOI] [PubMed] [Google Scholar]
  22. Nicklin, P, Bergman, P, Zhang, B, Triantafellow, E, Wang, H, Nyfeler, B et al. (2009). Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 136: 521–534. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Zhang, J, Fan, J, Venneti, S, Cross, JR, Takagi, T, Bhinder, B et al. (2014). Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion. Mol Cell 56: 205–218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Ye, J, Kumanova, M, Hart, LS, Sloane, K, Zhang, H, De Panis, DN et al. (2010). The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation. EMBO J 29: 2082–2096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Harding, HP, Zhang, Y, Bertolotti, A, Zeng, H and Ron, D (2000). Perk is essential for translational regulation and cell survival during the unfolded protein response. Mol Cell 5: 897–904. [DOI] [PubMed] [Google Scholar]
  26. Whitecar, JP Jr, Bodey, GP, Harris, JE and Freireich, EJ (1970). L-asparaginase. N Engl J Med 282: 732–734. [DOI] [PubMed] [Google Scholar]
  27. Asselin, BL. Asparaginase in treatment of acute leukemias. New Directions for Clinical Research. Pui CH (ed.). Humana, Totawa, NJ, 2003. pp. 365–379. [Google Scholar]
  28. Asparaginase treatment in treatment of acute leukemias. New Directions for Clinical Research. Pui CH (ed.). Humana, Totawa, NJ, 2003. pp. 381–391. [Google Scholar]
  29. Hays, JL, Kim, G, Walker, A, Annunziata, CM, Lee, JM, Squires, J et al. (2013). A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety. Mol Clin Oncol 1: 565–569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Müller, HJ and Boos, J (1998). Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 28: 97–113. [DOI] [PubMed] [Google Scholar]
  31. Balasubramanian, MN, Butterworth, EA and Kilberg, MS (2013). Asparagine synthetase: regulation by cell stress and involvement in tumor biology. Am J Physiol Endocrinol Metab 304: E789–E799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Kim, K, Jeong, JH, Lim, D, Hong, Y, Yun, M, Min, JJ et al. (2013). A novel balanced-lethal host-vector system based on glmS. PLoS ONE 8: e60511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Song, M, Kim, HJ, Kim, EY, Shin, M, Lee, HC, Hong, Y et al. (2004). ppGpp-dependent stationary phase induction of genes on Salmonella pathogenicity island 1. J Biol Chem 279: 34183–34190. [DOI] [PubMed] [Google Scholar]
  34. Englesberg, E (1971). Metabolic pathways. In: Vogel, HJ (ed.). Metabolic Regulation. Academic Press: New York. pp. 257–296. [Google Scholar]
  35. Jennings, MP and Beacham, IR (1990). Analysis of the Escherichia coli gene encoding L-asparaginase II, ansB, and its regulation by cyclic AMP receptor and FNR proteins. J Bacteriol 172: 1491–1498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Ando, M, Sugimoto, K, Kitoh, T, Sasaki, M, Mukai, K, Ando, J et al. (2005). Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol 130: 860–868. [DOI] [PubMed] [Google Scholar]
  37. Patel, N, Krishnan, S, Offman, MN, Krol, M, Moss, CX, Leighton, C et al. (2009). A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase. J Clin Invest 119: 1964–1973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Story, MD, Voehringer, DW, Stephens, LC and Meyn, RE (1993). L-asparaginase kills lymphoma cells by apoptosis. Cancer Chemother Pharmacol 32: 129–133. [DOI] [PubMed] [Google Scholar]
  39. van den Berg, H (2011). Asparaginase revisited. Leuk Lymphoma 52: 168–178. [DOI] [PubMed] [Google Scholar]
  40. Daegelen, P, Studier, FW, Lenski, RE, Cure, S and Kim, JF (2009). Tracing ancestors and relatives of Escherichia coli B, and the derivation of B strains REL606 and BL21(DE3). J Mol Biol 394: 634–643. [DOI] [PubMed] [Google Scholar]
  41. Carmichael, J, DeGraff, WG, Gazdar, AF, Minna, JD and Mitchell, JB (1987). Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936–942. [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Figure S1
Click here for additional data file. (108.3KB, pdf)
Supplementary Figure S2
Click here for additional data file. (80.1KB, pdf)
Supplementary Figure S3
Click here for additional data file. (134.1KB, pdf)
Supplementary Figure S4
Click here for additional data file. (97.2KB, pdf)
Supplementary Figure S5
Click here for additional data file. (59.1KB, pdf)

Articles from Molecular Therapy Oncolytics are provided here courtesy of American Society of Gene & Cell Therapy

RESOURCES